Daniel Janiak Overview
Daniel Janiak General Information
Dr. Daniel Janiak serves as Chief Operating Officer at Trotana Therapeutics. He is an Angel Investor. He Co-Founded & served as a Board Member at Apsara Therapeutics. Dr. Daniel Janiak served as a Partner at Mercury Fund. He focuses on developing and originating science-based investment themes and startup opportunities. Before joining Mercury, Danny was an Associate in the Physical and Biological Technologies practice at In-Q-Tel, the strategic venture investment arm of the U.S. Intelligence Community. While at In-Q-Tel, Danny was responsible for the management and oversight of technology development programs in numerous In-Q-Tel portfolio companies. In addition, he was responsible for leading technical due diligence on all potential investment candidates in the advanced materials space. Danny received his B.S. and Ph.D. from the University of Maryland where he was a Future Faculty Fellow and held the Robert E. Fischell Fellowship in Biomedical Engineering. In addition, Danny has been selected to participate in the Kauffman Fellows Program through the Center for Venture Education. Danny is currently a board observer of Mercury Fund portfolio companies Confluence, DNAtrix, Marval Biosciences, and Swift Biosciences. Outside of DFJ Mercury, He holds a Ph.D. (Doctor of Philosophy) and a BS in Material Science from the University of Maryland.
000000 000000 00.0
Daniel Janiak Investments by Industry, Year, and Region
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog »
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »